Labetalol Injection Shortage, Estimated Release Dates of January to Third Quarter 2019

January 30, 2019

ASHP and are reporting a shortage of labetalol injection due to increased demand and manufacturing delays. Products affected include:

  • 5 mg/mL, 20 mL vials
    • Hikma vials are on allocation.
    • Pfizer estimates a release date of third quarter 2019.
    • No release date from Alvogen or Akorn.
  • 5mg/mL, 40 mL vials
    • Pfizer estimates a release date of January 2019.
    • Hikma estimates a release date of February to March 2019.
    • No release date from Alvogen or Akorn.
  • 5 mg/mL 4 mL Carpuject syringe, 10 count
    • Pfizer estimates a release date of first quarter 2019.

Intravenous labetalol, intravenous hydralazine, and oral nifedipine are all equally acceptable first-line treatments for acute hypertension in pregnancy and are typically chosen based on the clinical scenario. In a case of a shortage such as this, additional factors contribute to how these choices might be made. Obstetric providers should work with their hospitals and health systems to mitigate the effects on patient care of this shortage, for instance, by working on judicious approaches that reserve supplies of labetalol for patients with limited options, such as pregnant women.

For more information, see Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period or Chronic Hypertension in Pregnancy.


American College of Obstetricians and Gynecologists
409 12th Street SW, Washington, DC  20024-2188
Mailing Address: PO Box 96920, Washington, DC 20024-9998